ClinicalTrials.gg
Not yet recruitingNCT07581301FAST-AIDUpdated Sep 9, 2026

Administering Atropine Through Autoinjectors Within Ambulance Services for Poisoning Patients in Sri Lanka's North Central Province

An observational study in Pesticide Poisoning, sponsored by University of Edinburgh. Not yet recruiting at 1 site in Sri Lanka. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by University of Edinburgh · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Study summary

Pesticide poisoning remains one of the most serious public health challenges in rural Sri Lanka, particularly in the North Central Province (NCP), where intensive farming and heavy pesticide use have led to high rates of accidental and intentional poisoning. Although the antidote, atropine, is routinely used in hospitals, delays in receiving treatment often occur because patients must travel long distances before reaching care. Early initiation of treatment is critical, and survival depends on the speed with which atropine is administered.

The government's free 1990 Suwa Seriya ambulance service, established in 2016, provides emergency transport across Sri Lanka but currently has limited capacity for administering time-sensitive antidotes. Community consultations conducted during an earlier study revealed that people preferred life-saving treatments such as atropine to be managed through the formal health system, rather than stored in villages. This led to the idea of exploring whether ambulance staff could safely use atropine autoinjectors; simple, pre-filled devices that deliver the drug quickly and can safely be used even by non-medical professionals.

The FAST-AID study aims to assess the feasibility of introducing atropine autoinjectors into Sri Lanka's emergency ambulance system for use in pesticide poisoning cases. The main question is:

How feasible is it to integrate atropine autoinjectors into the ambulance service to provide earlier treatment for pesticide poisoning patients? Secondary questions explore (1) how ambulance coverage and travel routes affect timely administration; (2) how ambulance and hospital staff experience the use of the devices; and (3) how patients perceive the care they received.

The study will be carried out in the Anuradhapura District of the NCP, in collaboration with the Suwa Seriya ambulance service and selected hospitals. Two geographical clusters, one densely populated and one more remote, have been chosen to compare different service conditions. Around 30 pesticide poisoning patients will receive atropine using autoinjectors during ambulance transport, under guidance from an on-call emergency physician.

Data will be collected through several complementary methods:

  • Operational data from ambulance and hospital records (e.g., response times, use of autoinjectors, patient outcomes).
  • Geographic mapping (GIS) of ambulance coverage to assess accessibility and response patterns.
  • Focus group discussions with ambulance and hospital staff to explore training, practical challenges, and perceptions of the intervention.
  • Semi-structured interviews with patients to understand their lived experience of emergency care.
  • Participant observation in ambulances and hospitals to capture the everyday realities of emergency response.

Participants will be adults (aged 18 or above) who either work in the ambulance or hospital system or who have experienced pesticide poisoning and received atropine during the study period. All participants will provide written informed consent.

The research team will include Sri Lankan and UK collaborators from the University of Edinburgh and the South Asian Clinical Toxicology Research Collaboration (SACTRC).

By assessing the operational and social feasibility of using atropine autoinjectors in ambulances, this study aims to strengthen Sri Lanka's emergency response system and provide a foundation for a larger trial that could ultimately help save lives of those experiencing pesticide poisoning.

02

Conditions studied

  • Pesticide Poisoning

Browse trials for

Keywords

  • Pesticide Poisoning
  • Pre-Hospital Care
  • Atropine
  • Autoinjectors
03

In context

Poisoning

98 studies on the registry are indexed under Poisoning; 16 are open to participants now.

This study's planned enrollment of 30 is below the median of 122 across 41 observational studies indexed under Poisoning.

Browse Poisoning studies →

Lead sponsor

University of Edinburgh is the lead sponsor of 403 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study will involve three participant groups drawn from the Anuradhapura District in the North Central Province of Sri Lanka:

  • Ambulance staff (Emergency Medical Technicians, drivers, and support staff) working within the Suwa Seriya 1990 ambulance service who administer atropine autoinjectors during the pilot period.
  • Hospital staff (doctors and nurses) working in Emergency Treatment Units (ETUs) of the hospitals in two geographical clusters, one densely populated and one more remote, that receive pesticide poisoning patients treated with atropine autoinjectors.
  • Pesticide poisoning patients (men and women aged 18 years and above) who have received atropine via autoinjector from ambulance staff during the pilot period.

The total expected sample size is approximately 30 pesticide poisoning patients, and all ambulance and hospital staff directly involved in these 30 cases will also be invited to participate in focus group discussions.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants over the age of 18 who are willing and able to provide written will be asked to participate in the study.
  • Ambulance staff directly involved in the management and response to pesticide poisoning cases during the intervention period in the selected two geographical clusters.
  • Doctors and nurses from selected hospitals in the two geographical clusters who managed pesticide poisoning patients that received atropine via autoinjectors administered by ambulance staff during the intervention period.
  • Pesticide poisoning patients managed by Suwa Seriya ambulances in the selected two geographical clusters of the Anuradhapura district during the intervention period.

Exclusion criteria

Exclusion Criteria:

  • Participants who are unwilling or unable to provide written will not be included in the study.
  • Participants who do not speak Sinhala.
  • Participants under the age of 18 years.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with suspected pesticide poisoning attended by ambulance services

    The cohort includes individuals with suspected pesticide poisoning attended by participating Suwa Seriya 1990 ambulances in the North Central Province of Sri Lanka. Cases are identified at the pre-hospital stage based on reported exposure and clinical presentation, reflecting real-world emergency conditions where diagnostic confirmation is often unavailable at first contact.

    Device: Pre-hospital Atropine Autoinjector Administration

Interventions

  • DevicePre-hospital Atropine Autoinjector Administration

    Administration of atropine via pre-filled autoinjector by trained ambulance staff of the Suwa Seriya 1990 for patients with suspected pesticide poisoning in the pre-hospital setting. Selected ambulances will be equipped with atropine autoinjectors, and staff will receive training on identification of poisoning cases, indications for atropine use, dosing, and safe administration. The intervention is implemented during routine emergency response, with atropine administered when clinically indicated prior to hospital arrival. This intervention aims to enable earlier delivery of atropine and improve initial management within the emergency care pathway.

06

What researchers measure

Primary outcomes

  1. Time from ambulance arrival to atropine administration

    Measured in minutes from ambulance arrival at the scene to administration of atropine via autoinjector.

    Time frame: From ambulance arrival at scene until hospital admission (typically within 0-2 hours)

  2. Proportion of eligible patients receiving atropine via autoinjector

    Defined as the number of suspected pesticide poisoning cases attended by participating Suwa Seriya 1990 ambulances who receive atropine via autoinjector, divided by the total number of eligible cases.

    Time frame: From ambulance arrival at scene until atropine administration or hospital admission, whichever occurs first (typically within 0-2 hours)

Secondary outcomes

  1. Ambulance response time

    Time from emergency call dispatch to arrival at the scene.

    Time frame: From emergency call dispatch to ambulance arrival at scene (typically within 0-60 minutes)

  2. Time to atropine administration (minutes) from reported pesticide exposure (ambulance records)

    Measured as the time interval in minutes between the estimated time of pesticide exposure (as reported by the patient or bystanders and documented by emergency medical technicians) and the time of atropine administration via autoinjector recorded in ambulance patient care records of the Suwa Seriya 1990. This measure will be recorded only for cases where both time points are available.

    Time frame: From estimated time of exposure to atropine administration, assessed up to 6 hours

  3. Adverse events related to atropine administration

    Defined as the number of participants with any documented adverse reactions following atropine administration via autoinjector, as recorded in ambulance and hospital records.

    Time frame: From time of atropine administration to hospital admission, assessed up to 2 hours

  4. Glasgow Coma Scale (GCS) score at hospital arrival

    Measured using the Glasgow Coma Scale (GCS), a standardized clinical assessment of level of consciousness ranging from 3 to 15, as recorded at the time of hospital admission following transport by Suwa Seriya 1990.

    Time frame: At hospital admission

07

Study locations

1 site
  • South Asian Clinical Toxicology Collaboration
    Anuradhapura, North Central Province 50000, Sri Lanka
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
May 12, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
Dec 1, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07581301
Collaborators
University of Peradeniya
Responsible party
Sponsor
First posted
May 12, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Michael Eddleston, PhD
Contact
M.Eddleston@ed.ac.uk
+44-131-242-1383

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion